Loading stock data…
RCEL
$4.11-0.07 (-1.56%)
Market ClosedLast close May 8
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AVITA Medical, Inc. in the Healthcare sector is trading at $4.11. The stock is currently 45% below its 52-week high of $7.43, remaining 6.4% below its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why RCEL maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.11
Potential Upside
5%
Whystock Fair Value$4.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harves...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$143.05M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
291.81%
Volume
Today's trading volume
214,918
Recent News
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Undervalued Small Caps With Insider Buying Across Regions
Over the last 7 days, the United States market has risen by 4.2%, contributing to a substantial 29% climb over the past year, with earnings forecasted to grow by 16% annually. In this environment, identifying stocks that are both undervalued and have insider buying can present intriguing opportunities for investors seeking potential growth within small-cap sectors.
Undervalued Small Caps With Insider Buying To Explore In April 2026
The United States market has shown robust performance, climbing 4.4% in the last week and gaining 32% over the past year, with earnings expected to grow by 16% annually. In this thriving environment, identifying small-cap stocks that are undervalued and exhibit insider buying can offer intriguing opportunities for investors looking to capitalize on potential growth.
Exploring 3 Undervalued Small Caps With Insider Buying Across Regions
Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings forecasted to grow by 16% annually. In this context of fluctuating performance, identifying small-cap stocks with potential insider buying can be an intriguing strategy for investors seeking opportunities that may not be immediately apparent in larger market trends.
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade
The consensus price target hints at a 29.9% upside potential for Avita Medical (RCEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.